Trials / Completed
CompletedNCT02170727
A Phase 3 Study of a Daclatasvir/Asunaprevir/BMS-791325 Fixed Dose Combination (FDC) in Subjects With Chronic Hepatitis C Genotype 1
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 199 (actual)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
To demonstrate the effectiveness of Daclatasvir (DCV) 3 Direct Acting Antivirals (DAA) fixed dose combination in Genotype 1 Chronic Hepatitis C subjects.
Detailed description
US National Institutes of Health Division of AIDs (DAIDS)
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | DCV/ASV/BMS-791325 |
Timeline
- Start date
- 2014-06-26
- Primary completion
- 2015-06-12
- Completion
- 2015-09-09
- First posted
- 2014-06-23
- Last updated
- 2020-10-29
- Results posted
- 2019-08-16
Locations
20 sites across 3 countries: Russia, South Korea, Taiwan
Source: ClinicalTrials.gov record NCT02170727. Inclusion in this directory is not an endorsement.